KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $291.3 million.

  • Bio-Rad Laboratories' Operating Expenses rose 271.51% to $291.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year increase of 90.1%. This contributed to the annual value of $1.1 billion for FY2025, which is 90.1% up from last year.
  • As of Q4 2025, Bio-Rad Laboratories' Operating Expenses stood at $291.3 million, which was up 271.51% from $278.1 million recorded in Q3 2025.
  • Bio-Rad Laboratories' 5-year Operating Expenses high stood at $300.5 million for Q1 2023, and its period low was $244.7 million during Q3 2023.
  • In the last 5 years, Bio-Rad Laboratories' Operating Expenses had a median value of $278.3 million in 2022 and averaged $277.1 million.
  • In the last 5 years, Bio-Rad Laboratories' Operating Expenses surged by 2336.26% in 2021 and then plummeted by 1452.4% in 2022.
  • Bio-Rad Laboratories' Operating Expenses (Quarter) stood at $280.5 million in 2021, then dropped by 0.76% to $278.4 million in 2022, then decreased by 2.66% to $271.0 million in 2023, then increased by 4.65% to $283.6 million in 2024, then increased by 2.72% to $291.3 million in 2025.
  • Its Operating Expenses stands at $291.3 million for Q4 2025, versus $278.1 million for Q3 2025 and $268.2 million for Q2 2025.